Regeneron Pharmaceuticals Inc. (1REGN)
MTA
Real-time Data
07:00 AM
Day's Range
718.8052 wk Range
467.50Overview - 1REGN - Regeneron Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
57.12B
P/E (Trailing)
‪20.61‬
PEG Ratio
‪-4.40‬
Price / Sales (TTM)
‪4.72‬
Price / Book
‪2.63‬
EV / EBITDA
‪14.18‬
Profitability
Gross Margin
‪86.56%‬
Profit Margin
‪27.86%‬
Operating Margin
‪33.10%‬
Return on Assets
‪6.52%‬
Return on Equity
‪14.04%‬
Ownership
Shares Outstanding
103.13M
Float
95.79M
Held by Insiders
‪2.08%‬
Held by Institutions
‪93.44%‬
Price stats
Beta
‪0.18‬
50-Day Avg
‪605.96‬
200-Day Avg
‪624.87‬
Dividends
Payout Ratio
‪9.01%‬
Frequency
Quarterly
Market Cap - 1REGN - Regeneron Pharmaceuticals Inc.
Peers - 1REGN - Regeneron Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1REGNMTARegeneron Pharmaceuticals Inc.73.52BMarket Cap+28.94%52-week change20.57P/E (Trailing)‪27.86%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated107.27BMarket Cap+27.82%52-week change32.13P/E (Trailing)‪34.99%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals Inc45.81BMarket Cap-89.61%52-week change41.96P/E (Trailing)‪16.12%‬Profit Margin
- 1ALABMTAASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)42.67BMarket Cap+47.15%52-week change140.57P/E (Trailing)‪30.74%‬Profit Margin
- 1INSMMTAInsmed Inc30.28BMarket Cap+16.20%52-week change-17.19P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-16.74%52-week change50.83P/E (Trailing)‪13.01%‬Profit Margin
- 1INCYMTAIncyte Corporation17.89BMarket Cap+33.27%52-week change16.48P/E (Trailing)‪27.70%‬Profit Margin
Profile Summary - 1REGN - Regeneron Pharmaceuticals Inc.
About
Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye diseases such as wet age-related macular degeneration and diabetic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
